| Execution period | Valid up to September 2030 |
|---|
BSE filing, BSE: 543963. Summary written from the filing by ALFA Finder's alert engine.
Shelter Pharma Ltd: key numbers
- Share price
- ₹39.60
- Market cap
- ₹68.52 Cr
- Revenue (annual)
- ₹73.13 Cr
- Net profit (annual)
- ₹9.03 Cr
- P/E (TTM)
- 7.6×Sector 46.1×
- Promoter holding
- 46.11%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shelter Pharma Ltd
All →Shelter Pharma Other Announcement
Shelter Pharma Ltd filed its shareholding pattern under Regulation 31(1)(c). The filing reports promoter, public and category-wise holdings without any transaction.
Shelter Pharma Preferential Issue
Shelter Pharma Ltd has allotted 4,65,000 equity shares via a preferential issue at ₹42.25 per share. This transaction resulted in a total capital infusion of ₹1.96 Crore.
- Value
- ₹1.96 Cr
Shelter Pharma Convertible Warrants
Shelter Pharma Limited approved the conversion of 465,000 warrants into equity shares for its promoter. This allotment follows the receipt of the remaining exercise price of Rs. 1.47 Crore.
- Value
- ₹1.47 Cr
Shelter Pharma Other Announcement
Shelter Pharma Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026. This is a routine regulatory compliance disclosure.
Shelter Pharma Management Change
Shelter Pharma Limited has regularized Ms. Vinita Shivraj Gadhavi as a Non-Executive Independent Director for a five-year term, following approval by shareholders at the 19th AGM.
Shelter Pharma Annual General Meeting
Shelter Pharma Limited conducted its 19th Annual General Meeting on September 29, 2026. Key agenda items included adopting financial statements and ratifying material related party transactions.
Other regulatory approval announcements
All →Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.
Mukka Proteins Regulatory Approval
Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.
- Execution
- October 1, 2026 to December 31, 2027
Canara Bank Regulatory Approval
Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.
- Value
- ₹1,500 Cr
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.